Bolt Biotherapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Bolt Biotherapeutics, Inc. (BOLT) had Debt Securities, Available-for-sale, Amortized Cost of $5.25 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $5.25M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $12.30M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $20.13M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $21.05M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $5.25M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $12.30M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $20.13M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $21.05M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $38.88M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $49.52M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $62.90M 10-K · filed 2026-03-12 |
| 2024-09-30 | $74.82M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $94.34M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $108.58M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $117.76M 10-K · filed 2025-03-24 |
| 2023-09-30 | $132.38M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $143.87M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $156.36M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $184.51M 10-K · filed 2024-03-21 |
| 2022-09-30 | $200.65M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $202.80M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $202.58M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $244.50M 10-K · filed 2023-03-29 |
| 2021-09-30 | $266.92M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $252.65M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $207.49M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $17.30M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |